Generation of Small Molecule Asthma Disease Modifying Agents from a TB Derived Peptide Lead

从结核病衍生肽先导物中生成小分子哮喘疾病调节剂

• 批准号: 132658
• 金额: $ 17.74万
• 依托单位: PEPTINNOVATE LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=132658
• 关键词: Generation; Small; Molecule; Asthma; Disease

Peptinnovate is a drug discovery and development company based in the Stevenage Bioscience Catalyst on the GSK site. The company's core research is based on molecules derived from Mycobacterium tuberculosis proteins as innovative immunomodulatory agents for the treatment of chronic inflammatory diseases. The lead molecule PIN201104 is an extremely safe, low molecular weight peptide identified by phenotypic drug discovery in collaboration with a number of leading UK academic groups. PIN201104 is being progressed into the clinic as a first in class disease modifying agent for the treatment of asthma and other chronic inflammatory conditions. Peptinnovate through this grant will exploit the disease modifying approach it has identified for PIN201104 to generate small molecule analogues. Further modification of these analogues subsequent to this project will allow the generation of orally active disease modifying agents for the treatment of mild to moderate asthmatics. There are currently no disease modifying agents available for the treatment of asthma. Peptinnovate is pioneering the discovery of agents with the potential to change the underlying disease of chronic inflammatory asthma and lead to potential curative therapies.

Peptinnovate是一家药物发现和开发公司，位于GSK网站上的Stevenage Bioscience Catalyst。该公司的核心研究是基于结核分枝杆菌蛋白衍生的分子，作为治疗慢性炎症性疾病的创新免疫调节剂。前导分子PIN 201104是一种非常安全的低分子量肽，通过与许多领先的英国学术团体合作进行的表型药物发现来鉴定。PIN201104正在进入临床，作为治疗哮喘和其他慢性炎症的第一种疾病调节剂。Peptinnovate将利用PIN201104确定的疾病修饰方法来产生小分子类似物。该项目之后对这些类似物的进一步修饰将允许产生用于治疗轻度至中度哮喘的口服活性疾病调节剂。目前没有可用于治疗哮喘的疾病调节剂。Peptinnovate是发现有可能改变慢性炎症性哮喘基础疾病并导致潜在治愈性疗法的药物的先驱。